Journal: microPublication Biology

Article Title: AAV-BR1 does not target endothelial cells in Sprague Dawley rats unlike in mice

doi: 10.17912/micropub.biology.001120

Figure Lengend Snippet:

Article Snippet: AAV-CAG-GFP (AAV Serotype BR1) , SignaGen Laboratories (SL116035; Titer: > 1x10 13 VG/mL) , Retrieved from Company website: AAV(BR1)-CAG-GFP is a pre-packaged rAAV in serotype BR1 (with capsid from AAV serotype BR1 and 2xITR from AAV serotype 2) which over-expresses EGFP under CAG (also known as CBA) promoter. CAG promoter is a combination of the cytomegalovirus (CMV) early enhancer element and chicken beta-actin promoter for high levels of gene expression in mammalian expression vectors. Ready to use format..

Techniques: Gene Expression, Expressing

Journal: Frontiers in Molecular Neuroscience

Article Title: Ras-related protein Rab-20 inhibition alleviates cerebral ischemia/reperfusion injury by inhibiting mitochondrial fission and dysfunction

doi: 10.3389/fnmol.2022.986710

Figure Lengend Snippet: shRNA, siRNA, and primers.

Article Snippet: AAV9-Syn-GFP-U6-shRab20 (shRab20) and AAV9-Syn-GFP-U6-negative control (shNC) were constructed by Sunbio Medical Biotechnology (Shanghai, China).

Techniques: shRNA

Journal: Frontiers in Molecular Neuroscience

Article Title: Ras-related protein Rab-20 inhibition alleviates cerebral ischemia/reperfusion injury by inhibiting mitochondrial fission and dysfunction

doi: 10.3389/fnmol.2022.986710

Figure Lengend Snippet: Ras-related protein Rab-20 knockdown significantly reduced the cerebral infarction and ameliorated the neurological outcome after cerebral I/R. (A) The shRab20 and shNC AAV particles were stereotactically injected into the right lateral ventricle for 4 weeks prior to MCAO operation. Scale bar, 500 μm. (B) Diagram of the experimental procedure. (C) The silencing efficiency of the shRab20 AAV particles in the penumbra of the cortex and hippocampus was determined by double immunofluorescence staining for Rab20 (red) in neuron (NeuN, blue) at 3 days after I/R. Scale bar, 20 and 50 μm. (D) Western blot assay was used to confirm the silencing efficiency of the shRab20 AAV particles in the penumbra of the cortex and hippocampus at 3 days after I/R ( n = 6). (E) Representative photographs of coronal brain sections stained by TTC showing decreased infarct volume in shRab20-treated mice as compared to the shNC-treated mice at 3 days after I/R ( n = 6). (F) Neurological scores were used to evaluate the neurological function at 3 days after I/R ( n = 18). ** P < 0.01.

Article Snippet: AAV9-Syn-GFP-U6-shRab20 (shRab20) and AAV9-Syn-GFP-U6-negative control (shNC) were constructed by Sunbio Medical Biotechnology (Shanghai, China).

Techniques: Knockdown, Injection, Double Immunofluorescence Staining, Western Blot, Staining